Commonwealth Equity Services’s Protalix BioTherapeutics PLX Stock Holding History

Commonwealth Equity Services’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$42.2K	Sell	19,461 -152,311	-89%	-$378K	﹤0.01%	4215
2025 Q4	$309K	Hold	171,772	–	–	﹤0.01%	3628
2025 Q3	$381K	Sell	171,772 -25,025	-13%	-$40.8K	﹤0.01%	3414
2025 Q2	$291K	Buy	196,797 +146,772	+293%	+$300K	﹤0.01%	3609
2025 Q1	$128K	Buy	50,025 +25	+0.1%	+$60	﹤0.01%	3949
2024 Q4	$94K	Hold	50,000	–	–	﹤0.01%	3918
2024 Q3	$51K	Sell	50,000 -100	-0.2%	-$105	﹤0.01%	3935
2024 Q2	$59K	Hold	50,100	–	–	﹤0.01%	3876
2024 Q1	$63K	Hold	50,100	–	–	﹤0.01%	3862
2023 Q4	$89K	Hold	50,100	–	–	﹤0.01%	3689
2023 Q3	$83K	Sell	50,100 -100	-0.2%	-$179	﹤0.01%	3595
2023 Q2	$100K	Buy	50,200 +100	+0.2%	+$238	﹤0.01%	3571
2023 Q1	$105	Hold	50,100	–	–	﹤0.01%	3489
2022 Q4	$68K	Buy	+50,100	New	+$55K	﹤0.01%	3474
2022 Q1	–	Sell	-40,290	Closed	-$33K	–	3781
2021 Q4	$33K	Buy	+40,290	New	+$42.2K	﹤0.01%	3571
2017 Q2	–	Sell	-3,775	Closed	-$51K	–	2546
2017 Q1	$51K	Buy	+3,775	New	+$33.9K	﹤0.01%	2325

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Commonwealth Equity Services's PLX Position: Q1 2026 in Review

Commonwealth Equity Services reduced its Protalix BioTherapeutics (PLX) stake by 89% in Q1 2026, selling an estimated $378K and leaving 19,461 shares worth $42.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4215.

Commonwealth Equity Services first reported a position in PLX in Q1 2017 and has held it in 16 quarters since. The position peaked at $381K in Q3 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Commonwealth Equity Services held 19,461 shares of Protalix BioTherapeutics worth $42.2K as of Q1 2026.
Commonwealth Equity Services sold 152,311 Protalix BioTherapeutics shares in Q1 2026, an estimated $378K.
Protalix BioTherapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #4215 holding.
Commonwealth Equity Services first reported a position in Protalix BioTherapeutics in Q1 2017 and has held it in 16 quarters since.
Commonwealth Equity Services's Protalix BioTherapeutics position peaked at $381K in Q3 2025.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.